Stocks · News reference
Filed: 2026-08-07 AccNo: 0001193125-26-339292 Size: 542 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Atossa Therapeutics (NASDAQ:ATOS) reported quarterly losses of $(0.95) per share which beat the analyst consensus estimate of $(1.02) by 6.86 percent. This is a 171.43 percent decrease over losses of $(0.35) per share
Peer-reviewed preclinical study published in npj Breast Cancer identifies new chemical entities with activity in ESR1-mutant modelsFindings suggest potential for combination with abemaciclibSEATTLE, July 28, 2026
Preclinical Data Poster Highlights Dual Estrogen Receptor and PKC-β/AKT Pathway Modulation as a Potential Therapeutic Strategy for Estrogen-Driven Pathology in McCune-Albright syndromeSEATTLE, July 21, 2026 /PRNewswire/